Stock NSPR INSPIREMD, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases InspireMD, Inc.

Equities

NSPR

US45779A8466

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.75 USD +7.42% Intraday chart for InspireMD, Inc. +8.27% -2.14%
May. 14 Transcript : InspireMD, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 14 Earnings Flash (NSPR) INSPIREMD Posts Q1 Revenue $1.5M, vs. Street Est of $1.9M MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption Clinical Trial of CGuard at LINC 2024
AQ
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024  
AQ
InspireMD : Reports First Quarter 2024 Financial Results and Provides Business Update
PU
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th
AQ
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
AQ
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
AQ
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
AQ
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
AQ
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
AQ
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
AQ
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
AQ
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System
AQ
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
AQ
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
InspireMD to Participate in Upcoming November Investor Conferences
AQ
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23
AQ
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th - InspireMD
AQ
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th
AQ
InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients
AQ
InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NSPR Stock
  4. News InspireMD, Inc.
  5. Press Releases